<span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">atezolizumab based treatment</span> <span style="margin-left: 3em;">atezolizumab plus bevacizumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">nivolumab based treatment</span> <span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab plus lenvatinib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">sintilimab based treatment</span> <span style="margin-left: 3em;">sintilimab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">VEGF(R) inhibitor</span> <span style="margin-left: 1em;">sorafenib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
progression or deaths (PFS) (2) DOR (2) deaths (OS) (2) objective responses (ORR) (2) AE (any grade) (1) SAE (any grade) (1) AE leading to treatment discontinuation (any grade) (1) AE (grade 3-4) (1) TRAE leading to discontinuation (any grade) (1) AE leading to death (grade 5) (1) STRAE (grade 3-4) (1) Fatigue TRAE (grade 3-4) (1) Nausea TRAE (grade 3-4) (1) Decreased appetite TRAE (grade 3-4) (1) Asthenia TRAE (grade 3-4) (1) Thrombocytopenia TRAE (grade 3-4) (1) Alopecia TRAE (grade 3-4) (1) Hypertension TRAE (grade 3-4) (1) Pruritus TRAE (grade 3-4) (1) Rash TRAE (grade 3-4) (1) Diarrhoea TRAE (grade 3-4) (1) Increased ALT TRAE (grade 3-4) (1) Increase AST TRAE (grade 3-4) (1) Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (1) Infusion-related reactions TRAE (grade 3-4) (1) Proteinuria TRAE (grade 3-4) (1) Diarrhoea AE (grade 3-4) (1) Rash AE (grade 3-4) (1) Increased ALT AE (grade 3-4) (1) Increase AST AE (grade 3-4) (1) Pyrexia AE (grade 3-4) (1) Weight decreased AE (grade 3-4) (1) Pruritus AE (grade 3-4) (1) Nausea AE (grade 3-4) (1) Vomiting AE (grade 3-4) (1) Constipation AE (grade 3-4) (1) Dyspnoea AE (grade 3-4) (1) Cough AE (grade 3-4) (1) Abdominal pain AE (grade 3-4) (1) Fatigue AE (grade 3-4) (1) Asthenia AE (grade 3-4) (1) Decreased appetite AE (grade 3-4) (1) Hypertension AE (grade 3-4) (1) Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) (1) Proteinuria AE (grade 3-4) (1) Anaemia AE (grade 3-4) (1) Dyspepsia AE (grade 3-4) (1) Thrombocytopenia AE (grade 3-4) (1) Epistaxis AE (grade 3-4) (1) Acute kidney injury AE (grade 3-4) (1) Infusion-related reaction AE (grade 3-4) (1) Alopecia AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 CheckMate 459, 2019 1 IMbrave-150, 2020 atezolizumab plus bevacizumab vs. nivolumab alone
atezolizumab plus bevacizumab better
0.68 [0.48; 0.98] 0.68 [0.48;0.98]atezolizumab plus bevacizumab vs. nivolumab alone
atezolizumab plus bevacizumab better
0.68 [0.48; 0.98] atezolizumab plus bevacizumab vs. sorafenib
atezolizumab plus bevacizumab better
0.58 [0.42; 0.80] 0.58 [0.42;0.80]atezolizumab plus bevacizumab vs. sorafenib
atezolizumab plus bevacizumab better
0.58 [0.42; 0.80] nivolumab alone vs. atezolizumab plus bevacizumab
atezolizumab plus bevacizumab better
1.47 [1.02; 2.10] 1.47 [1.02;2.10]nivolumab alone vs. atezolizumab plus bevacizumab
atezolizumab plus bevacizumab better
1.47 [1.02; 2.10] nivolumab alone vs. sorafenib
0.85 [0.71; 1.01] 0.85 [0.71;1.01]nivolumab alone vs. sorafenib
0.85 [0.71; 1.01] sorafenib vs. atezolizumab plus bevacizumab
atezolizumab plus bevacizumab better
1.72 [1.26; 2.36] 1.72 [1.26;2.36]sorafenib vs. atezolizumab plus bevacizumab
atezolizumab plus bevacizumab better
1.72 [1.26; 2.36] sorafenib vs. nivolumab alone
1.18 [0.99; 1.40] 1.18 [0.99;1.40]sorafenib vs. nivolumab alone
1.18 [0.99; 1.40] sorafenib nivolumab alone atezolizumab plus bevacizumab pembrolizumab plus lenvatinib sintilimab direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C sorafenib nivolumab alone atezolizumab plus bevacizumab pembrolizumab plus lenvatinib sintilimab sorafenib --- 1.18 0.99; 1.401.72 1.26; 2.36NA NA nivolumab alone 0.85 0.71; 1.01--- 1.47 1.02; 2.10NA NA atezolizumab plus bevacizumab 0.58 0.42; 0.800.68 0.48; 0.98--- NA NA pembrolizumab plus lenvatinib NA NA NA --- NA sintilimab NA NA NA NA ---
pathologies: 131
- treatments: 724
result logic